top of page

Biopharma Daily Stock Updates - 12/21/21

$XBI $116.58 +0.68%%


Covid Updates

$NVAX -5.4% Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study source

$GILD -0.9% European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression source

$CYDY +5.0% CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population source

Pipeline Updates

$EIGR -1.5% Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection source

$JAGX +20.0% Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA source

$DCPH +5.1% Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor source

$RIGL +1.5% Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia source

$TFFP +0.8% TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients source

$ADVM +0.5% Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022 source

$ZGNX +2.3% Zogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in Japan for the Treatment of Epileptic Seizures Associated with Dravet Syndrome source

$PHAS +0.4% PhaseBio Provides Pemziviptadil (PB1046) Program Update source

$URGN -3.6% First Patient Dosed in UroGen Pharma’s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC) source

$HEPA +1.7% Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer source

$CLSD -0.3% Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD source

$SLGL +2.1% Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY® source

$AZN +0.7% Ultomiris regulatory submission accepted under FDA Priority Review in the US for adults with generalised myasthenia gravis source

Business Updates

$HTBX -1.8% Heat Biologics Announces Planned Acquisition of Elusys Therapeutics source


Posted by JM



bottom of page